Transforming Vision

With Small Aperture OpticsYari L. MitchellVice President, Medical Affairs & Business Strategy

OIS@ASCRS – May 4, 2017

W o r d s

W o r d s

W o r d s

W o r d s

Y o u r W h o l e W o r l d

W o r d s

Single Focus Challenge

20/16 at Far

20/50 at Intermediate

20/100 at Near

-0.3

-0.2

-0.1

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

2.00 1.50 1.00 0.50 0.00 -0.50 -1.00 -1.50 -2.00 -2.50 -3.00 -3.50 -4.00

Lo

gM

AR

Ac

uit

y

Defocus (D)

Defocus CurveMean BCDVA

Functional

Range of

Vision

* Presbyopic patient defocus curve – KAMRA Inlay PMA (N=114)

Benefits of Small Aperture

-0.3

-0.2

-0.1

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

-4.00-3.50-3.00-2.50-2.00-1.50-1.00-0.500.000.501.001.502.00

Lo

gM

AR

Ac

uit

y

Defocus (D)

Binocular Defocus Curve (IC-8® IOL with Monofocal IOL)

* Mean BSCVA defocus curve collected in a subgroup at 6 months (N=12)

Functional

Range of

Vision

20/20 at Intermediate

20/30 at Near

20/16 at Far

Quantity and Quality

0.0D +0.5D +1.0D +1.5D +2.0D +3.0D

IC-8® IOL Target-corrected

to -0.75D

Symfony IOL

AcriLisa

Trifocal IOL

(Far Focus) (Near Focus)(Intermediate Focus)

The IC-8 IOL is not approved for use in the United States

KAMRA® Inlay IC-8® Intraocular Lens

Creating the Corneal Inlay Market

KAMRA® Inlay in the Real World

-0.2

-0.1

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Preop Month 1 Month 3 Month 6

LogM

AR

Acu

ity

Visit

UCDVA

UCDVA IE UCDVA OU

-0.20

-0.10

0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

Preop Month 1 Month 3 Month 6

LogM

AR

Acu

ity

Visit

UCNVA

UCNVA IE UCNVA OUN=337 N=248N=328N=271

KAMRA Inlay

Taking Share in a Crowded IOL Market

Uncorrected Visual Acuity

-0.1

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Mon 1 (n=108) Mon 3 (n=107) Mon 6 (n=105)

log

MA

R

Binocular UCVA (Mean, 95%CI)

Far Intermediate Near

European Post-Market IC-8® Study Outcomes

The IC-8 IOL is not approved for use in the United States

Virgin Eyes

86.5%

7.5%

5.4%0.3%

0.3%

Monofocal

Toric

Presbyopia-correcting

Phakic

Other

IC-8® IOL Opportunity

*Estimate based on prevalence of LVC, corneal aberrations > 0.5 microns and keratoconus and

reported 2016 US IOL adoption data from the 2016 Market Scope IOL Report

11%

Aberrated

Cornea Segment*

2016 Market Scope IOL Report – US IOL Adoption

The IC-8 IOL is not approved for use in the United States